Taiwan · Delayed Price · Currency is TWD Advagene Biopharma Statistics
Total Valuation
TPEX:6709 has a market cap or net worth of TWD 1.56 billion. The enterprise value is 1.40 billion.
| Market Cap | 1.56B |
| Enterprise Value | 1.40B |
Important Dates
The next estimated earnings date is Friday, March 20, 2026.
| Earnings Date | Mar 20, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
TPEX:6709 has 59.38 million shares outstanding. The number of shares has increased by 10.02% in one year.
| Current Share Class | 59.38M |
| Shares Outstanding | 59.38M |
| Shares Change (YoY) | +10.02% |
| Shares Change (QoQ) | +6.15% |
| Owned by Insiders (%) | 23.27% |
| Owned by Institutions (%) | 1.31% |
| Float | 30.23M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 8.35 |
| P/TBV Ratio | 8.35 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -19.70 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -18.19 |
Financial Position
The company has a current ratio of 30.83, with a Debt / Equity ratio of 0.02.
| Current Ratio | 30.83 |
| Quick Ratio | 30.73 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.05 |
| Interest Coverage | -357.26 |
Financial Efficiency
Return on equity (ROE) is -48.04% and return on invested capital (ROIC) is -29.93%.
| Return on Equity (ROE) | -48.04% |
| Return on Assets (ROA) | -28.28% |
| Return on Invested Capital (ROIC) | -29.93% |
| Return on Capital Employed (ROCE) | -38.33% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -5.93M |
| Employee Count | 12 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +26.56% in the last 52 weeks. The beta is 0.67, so TPEX:6709's price volatility has been lower than the market average.
| Beta (5Y) | 0.67 |
| 52-Week Price Change | +26.56% |
| 50-Day Moving Average | 28.60 |
| 200-Day Moving Average | 24.88 |
| Relative Strength Index (RSI) | 38.99 |
| Average Volume (20 Days) | 47,808 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -73.24M |
| Pretax Income | -71.10M |
| Net Income | -71.10M |
| EBITDA | -72.95M |
| EBIT | -73.24M |
| Earnings Per Share (EPS) | -1.23 |
Balance Sheet
The company has 167.68 million in cash and 4.01 million in debt, with a net cash position of 163.68 million or 2.76 per share.
| Cash & Cash Equivalents | 167.68M |
| Total Debt | 4.01M |
| Net Cash | 163.68M |
| Net Cash Per Share | 2.76 |
| Equity (Book Value) | 187.46M |
| Book Value Per Share | 3.16 |
| Working Capital | 184.64M |
Cash Flow
In the last 12 months, operating cash flow was -76.46 million and capital expenditures -574,000, giving a free cash flow of -77.03 million.
| Operating Cash Flow | -76.46M |
| Capital Expenditures | -574,000 |
| Free Cash Flow | -77.03M |
| FCF Per Share | -1.30 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
TPEX:6709 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -10.02% |
| Shareholder Yield | -10.02% |
| Earnings Yield | -4.54% |
| FCF Yield | -4.92% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |